Though BRCA and PALB2 mutations were relatively uncommon, tumors from BRCA- and PALB2-mutated patients had distinct mutational profiles compared to non-mutated patients, were more likely to be PD-L1 positive, and had a comparatively high tumor mutational burden (TMB). Here, PALB2 is linked to neoplasm.